Table 1.
Ongoing clinical trials and preclinical studies of SHP2 inhibitors.
| Inhibitor | Cancer type(s) | Clinical status | Notesa |
|---|---|---|---|
|
JAB-3068 (Jacobio Pharmaceuticals) |
Non-small cell lung cancer (NSCLC) Head and neck cancer Esophageal cancer |
Phase 1/2a | NCT03565003 |
|
JAB-3312 (Jacobio Pharmaceuticals) |
Non-small cell lung cancer (NSCLC) Colorectal cancer Pancreatic ductal carcinoma Esophageal squamous cell carcinoma Head and neck squamous cell carcinoma Breast cancer Other solid tumors |
Phase 1 | NCT04045496 |
|
TN0155b (Novartis) |
Non-small cell lung cancer (NSCLC) Esophageal squamous cell cancer (SCC) Head and neck SCC Gastrointestinal stromal tumors |
Phase 1/1b | |
|
RMC-4630 (Revolution Medicines) |
Solid tumors (unspecified) | Phase 1b/2 | NCT03989115 |
|
RLY-1971 (Relay Therapeutics) |
Solid tumors (unspecified) | Phase 1 | NCT04252339 |
| SHP099 |
Esophageal cancer cells Hematopoietic cancer cells Colorectal cancer cells KRAS-mutant cancer cells Triple-negative breast cancer |
No clinical trials; research involves cell lines and mouse xenografts57,100,106. |
ahttps://clinicaltrials.gov/ct2/ (identification number).
bCombination with spartalizumab or ribociclib.